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Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used and have been linked to acute
kidney injury (AKI), chronic kidney disease (CKD) and cardiovascular disease (CVD). Patients who survive an AKI
episode are at risk for future adverse kidney and cardiovascular outcomes. The objective of our study was to
examine the prevalence and predictors of NSAID use among AKI survivors.
Methods: The Southern Community Cohort Study is a prospective study of low-income adults aged 40–79 in the
southeastern US. Through linkage with Centers for Medicare and Medicaid Services, 826 participants with an AKI
diagnosis (ICD-9 584.5-584.9) at any age prior to cohort enrollment were identified. At baseline, data were collected
on regular use of prescription and over-the-counter NSAIDs, as well as demographic, medical and other
characteristics. Additional comorbidities were ascertained via linkage with CMS or the US Renal Data System.
Results: One hundred fifty-four AKI survivors (19%) reported regular NSAID use at cohort enrollment (52
prescription, 81 OTC, 21 both) and the percentage of NSAID users did not vary by time since AKI event. Over 58%
of users were taking NSAIDS regularly both before and after their AKI event. Hypertension (83%), arthritis (71%),
heart failure (44%), CKD (36%) and diabetes (35%) were prevalent among NSAID users. In a multivariable model,
history of arthritis (OR: 3.00; 95% CI: 1.92, 4.68) and acetaminophen use (OR: 2.43; 95% CI: 1.50, 3.93) were
significantly associated with NSAID use, while prevalent CKD (OR: 0.63; 95% CI: 0.41, 0.98) and diabetes (OR: 0.44;
95% CI: 0.29, 0.69) were significantly inversely associated.
Conclusions: NSAID use among AKI survivors is common and highlights the need to understand physician and
patient decision-making around NSAIDs and to develop effective strategies to reduce NSAID use in this vulnerable
population.
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Background
Acute kidney injury (AKI) is one of the fastest growing
conditions affecting the kidney and a risk factor for ac-
celerated loss of kidney function and cardiovascular
disease (CVD) [1–3]. Improving outcomes among the
growing population of AKI survivors requires identifying
modifiable risk factors to reduce these events. Non-
steroidal anti-inflammatory drugs (NSAIDs) are the
most commonly used analgesics worldwide and an
established risk factor for AKI [4, 5], chronic kidney
disease (CKD) [6], and CVD [7]. The American Society
of Nephrology (ASN) Quality and Patient Safety (QPS)
Task Force highlighted the avoidance of NSAIDs as a
high priority area “most open” to improvement in
patients with kidney disease [8]. Similarly, the US Food
and Drug Administration (FDA) recently strengthened
its warning regarding the link between NSAIDs and
major vascular events, particularly among those with
cardiovascular risk factors [9].
Despite growing attention to the dangers of NSAID use
among high-risk populations, use is common among pa-
tients with CKD, ranging between 4–31% depending on the
populations studied [10, 11]. However, to our knowledge,
no studies to date have examined their use in patients who
have experienced AKI. Given the high prevalence of CKD
in this population and evidence linking AKI to future kid-
ney and cardiovascular outcomes [12, 13], examining
NSAID use among survivors of AKI is important for identi-
fying the magnitude of the gap between patient and pro-
vider practice and guideline recommendations. To examine
the frequency of NSAID use among AKI survivors in a low
socioeconomic population which carries a disproportionate
risk of CKD and end-stage renal disease [14], as well as fac-
tors associated with NSAID use among AKI survivors, we
leveraged detailed analgesic intake information collected
from participants in the Southern Community Cohort
Study (SCCS), a large prospective cohort of low-income
adults in the southeastern US.
Methods
The SCCS is an ongoing, prospective cohort study designed
to study incident cancer and other chronic diseases. From
2002 through 2009, the SCCS enrolled nearly 86,000 adults
aged 40–79 years, two-thirds black, residing in 12 states in
the southeastern US. The study design and methods have
been described in detail [15]. Approximately 86% of partici-
pants were enrolled through community health centers
(CHC), institutions providing primary health and prevent-
ive care services in medically underserved areas and thus
serving generally low-income populations [14]. The
remaining 14% were recruited via mail-based general popu-
lation sampling. For all participants, data on socioeco-
nomic, demographic and lifestyle characteristics, as well as
personal medical and medication use history, were
ascertained at cohort enrollment using the same question-
naire, administered via standardized computer-assisted
personal interview for CHC participants, and via self-
administered mailed questionnaire for general population
participants (questionnaire at www.southerncommunitystu
dy.org). SCCS participants provided written informed
consent, and the Institutional Review Boards of Vanderbilt
University Medical Center and Meharry Medical College
approved all study protocols, which adhere to the Declar-
ation of Helsinki. We adhered to the guidelines and meth-
odology set forth in the Strengthening the Reporting of
Observational studies in Epidemiology Statement [16].
Study population and setting
We restricted our analyses to SCCS participants who had
an inpatient or outpatient AKI diagnosis prior to study en-
rollment, ascertained via linkage of the cohort, using Social
Security number, date of birth and first and last name, with
Centers for Medicare and Medicaid Services (CMS)
Research Identifiable Files from January 1, 1999 through
December 31, 2010. Prevalent AKI was defined using in-
patient and outpatient medical claims with ICD-9 code
584.5-584.9 within either the Medicare institutional (Medi-
care Provider Analysis and Review, MEDPAR), Part B
carrier or outpatient-based claims files (for those 65 years
and older), or the Medicaid Analytic Extract (MAX) In-
patient and Other Services claims files (for those under age
65 years) [17]. For those who had multiple AKI events re-
corded prior to enrollment, the one closest to enrollment
was selected as the index AKI event. A total of 1018 SCCS
participants with a diagnosis of AKI prior to enrollment in
the cohort (AKI survivors) were identified.
We excluded patients with a diagnosis of end-stage
renal disease (ESRD), ascertained by linkage with the
United States Renal Data System (USRDS) from January
1, 2002 through September 1, 2012. The USRDS
registers ESRD cases certified by a physician diagnosis
and filed using a medical evidence report form (to the
Medicare ESRD program) or when there is other evi-
dence of chronic dialysis or a kidney transplant irre-
spective of the glomerular filtration rate [18], providing
virtually complete ascertainment of all persons in the US
receiving treatment for ESRD. After exclusion of 192 in-
dividuals with a diagnosis of ESRD prior to SCCS enroll-
ment, a total of 826 AKI survivors were included in the
current analyses (see Additional file 1: Figure S1).
Ascertainment of regular analgesic use
At cohort enrollment, participants were asked: “In the
past year, have you taken any of the following medica-
tions regularly? By regularly, we mean at least two times
per week for one month or more.” Listed medications
included the names of both prescription (Celebrex,
Vioxx, Bextra) and over-the-counter (OTC) NSAIDs
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(including Advil, Motrin, Aleve, Ibuprofen, etc.) and
other analgesic medications, such as low-dose aspirin,
regular aspirin (Anacin, Bayer, Bufferin, Excedrin, etc.)
and acetaminophen (Tylenol). Those who responded
affirmatively were asked additional follow-up questions
regarding number of years of regular use and average
number of pills per week for each medication. From data
on self-reported duration of regular NSAID use and date
of index AKI CMS claim, a variable was created to indi-
cate whether the participant started taking NSAIDs
before or after the index AKI event.
For the purposes of estimating the prevalence of
NSAID use, a study participant was classified as a regu-
lar NSAID user if he or she reported regularly using
either prescription or OTC NSAIDs. If the participant re-
ported non-use or unknown use, he or she was classified
as NSAID non-user. This classification scheme provides
what we consider a lower bound on the prevalence of
NSAID use in the study population. For the purposes of
estimating relative measures of NSAID use, observations
missing the outcome were incorporated into the analysis
via multiple imputation, a method for missing data.
Assessment of comorbidities
Comorbidities were assessed in two ways. At baseline,
participants were asked whether they had ever received
a physician diagnosis of hypertension, diabetes, arthritis,
myocardial infarction/coronary artery bypass graft (MI/
CABG), and high cholesterol. We ascertained a history
of CKD and heart failure by linkage of the cohort with
CMS and were defined as the occurrence, prior to the
date of SCCS enrollment, of a medical claim with ICD-9
code 585.1-585.5 or 428.x, respectively.
Statistical analysis
Participants’ baseline characteristics were summarized as
medians (and corresponding 25th and 75th percentiles) for
continuous variables and counts (%) for categorical variables.
The primary estimates of prevalence used the “lower bound”
definition of NSAID use. Relative measures of use were esti-
mated via a multivariable model with the “yes/no/missing”
definition of NSAID use as the outcome. The multivariable
analysis of NSAID use began by specifying a priori a set of
covariates believed to be predictors of the outcome. The set
of covariates included demographic variables (age, sex, race,
education, income, recruitment source), indicators of co-
morbidities (heart failure, hypertension, diabetes, arthritis,
CKD), acetaminophen use and a variable for time since prior
AKI. The multivariable associations of NSAID use and the
list of covariates were estimated with a logistic regression
model. All available data were incorporated into the
model by using multiple imputation with predictive
mean matching to account for uncertain outcome data (234
patients) or predictor data (52 patients); 300 imputed
datasets were generated. After imputation, only two out-
come categories remained (yes/no) for the logistic regression
model. We also conducted a sensitivity analysis using the
complete-case definition (unknown NSAID users excluded),
the lower bound definition (unknown NSAID use consid-
ered as non-use, as described above) and multiple imput-
ation using only participants with an observed outcome. All
analyses were performed in R, free software for statistical
computing, version 3.2.5 (http://www.r-project.org/).
Results
Among 826 SCCS participants with a history of AKI
prior to enrollment, the median time between AKI event
and SCCS enrollment was 13.4 months (range 0.03–
121.02), and approximately 67% experienced their AKI
event within the prior two years. Overall, 19% (n = 154)
of AKI survivors reported regular use of NSAIDs at co-
hort enrollment, and the percentage of NSAID users did
not vary substantially by time since AKI event (Table 1).
Of the 154 NSAID users, 52 (34%) reported use of pre-
scription NSAIDs only, 81 (53%) reported OTC NSAID
use only, and the remaining 21 (14%) reported using
both prescription and OTC NSAIDs.
For prescription NSAIDs, the median duration of regu-
lar use was 2.0 years (25th percentile 0.5, 75th percentile
3.0) and the median number of pills per week was 7.0 (7.0,
14.0); corresponding numbers for OTC NSAIDs were 3.0
(1.0, 10.0) years and 7.5 (4.0, 14.8) pills per week, respect-
ively. Among NSAID users, 33.1% (51/154) reported regu-
lar NSAID use starting after their AKI event, whereas
58.4% (90/154) reported regular NSAID use starting prior
to their AKI claim and continuing to enrollment (data not
shown). Thirteen participants (8.4%) reported regular
NSAID use, but did not report when the use started.
Characteristics of AKI survivors who used NSAIDs (N =
154) and those who did not use NSAIDs (N = 438) or had
unknown NSAID use (N = 234) are presented in Table 2.
Table 1 Non-steroidal anti-inflammatory drug (NSAID) use
among 826 acute kidney injury (AKI) survivors in the Southern
Community Cohort Study, by time since most recent AKI event
prior to cohort enrollment
Timing of prior AKI (years) Patients, N (%) Taking NSAID, N (%)a
0.25 114 (13.8) 19 (16.7)
0.5 220 (26.6) 39 (17.7)
1 369 (44.7) 71 (19.2)
1.5 488 (59.1) 97 (19.9)
2 554 (67.1) 107 (19.3)
3 697 (84.4) 131 (18.8)
4 754 (91.3) 141 (18.7)
5 783 (94.8) 148 (18.9)
All records 826 (100) 154 (18.6)
aEither prescription or OTC NSAID or both
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Table 2 Characteristics of users and non-users of non-steroidal anti-inflammatory drugs (NSAIDs) among 826 acute kidney injury










NSAID users and non-usersd
Age at enrollment, years 57.5 (50.0, 66.0) 58.0 (50.0, 66.0) 57.0 (50.0, 65.0) 57.0 (50.0, 66.0) −0.5 (−4.1, 1.6)
Recruitment source
CHC 111 (72) 406 (93) 218 (93) 735 (89)
General population 43 (28) 32 (7) 16 (7) 91 (11)
Race
Black 79 (53) 280 (64) 176 (77) 535 (66)
White 66 (44) 137 (31) 42 (18) 245 (30)
Other 4 (3) 20 (5) 12 (5) 36 (4)
Male 66 (43) 215 (49) 108 (46) 389 (47) −6.2 (−15.8, 3.3)
Income < $15,000 113 (75) 336 (76) 190 (80) 629 (77) 1.1 (−7.3, 9.5)
Education
< High school 46 (31) 177 (41) 105 (47) 328 (41)
High school 46 (31) 141 (32) 70 (32) 257 (32)
> High school 57 (38) 118 (27) 47 (21) 222 (28)
Insurance coverage 143 (93) 398 (91) 204 (93) 204 (93) 2.4 (−2.8, 7.6)
Most recent doctor visit, months
0 53 (36) 185 (43) 86 (40) 324 (41)
1 56 (38) 133 (31) 79 (37) 268 (34)
2 20 (14) 33 (8) 24 (11) 77 (10)
3 19 (13) 76 (18) 26 (12) 121 (15)
BMI, kg/m2 30.0 (26.1, 36.7) 29.4 (25.6, 36.0) 29.2 (24.2, 35.9) 29.4 (25.3, 36.1) 0.7 (−0.5, 1.9)
Regular use of:
Low-dose aspirin 66 (44) 162 (37) 59 (27) 287 (36)
Regular aspirin 34 (24) 64 (15) 41 (19) 139 (18)
Acetaminophen 50 (35) 62 (14) 18 (9) 130 (17)
NSAID sourceb
Prescription 52 (34) - - 52 (34)
OTC 81 (53) - - 81 (53)
Both 21 (14) - - 21 (14)
Diabetes 54 (35) 233 (53) 114 (51) 401 (49) −18.1 (−27.4, −8.8)
Hypertension 128 (83) 348 (79) 181 (81) 657 (81) 3.7 (−3.8, 11.1)
Myocardial infarction 29 (19) 117 (27) 52 (23) 198 (24) −7.8 (−15.7, 0.2)
Arthritis 109 (71) 187 (43) 108 (48) 404 (50) 28.1 (19.1, 37.1)
Ulcer 41 (27) 77 (18) 38 (17) 156 (19) 9.0 (0.7, 17.3)
Lupus 4 (3) 6 (1) 4 (2) 14 (2) 1.2 (−2.0, 4.4)
High cholesterol 78 (51) 223 (51) 104 (47) 405 (50) −0.1 (−9.3, 9.2)
Heart failure 68 (44) 224 (51) 119 (51) 411 (50) −7.0 (−16.6, 2.6)
Chronic kidney disease 55 (36) 215 (49) 91 (39) 361 (44) −13.4 (−22.7, −4.0)
aData presented as median (25th, 75th percentile) for continuous variables and N (%) for categorical variables
bPercentages sum to >100% due to rounding
cn may not sum to 826 due to missing data
dPresented as median difference for continuous variables and proportion difference for categorical variables
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For both users and non-users of NSAIDs, median age at
SCCS enrollment was approximately 58 years, slightly
more than half were women, and approximately 75% had
an annual household income < $15,000. Over 90% re-
ported some form of health insurance coverage and 50%
reported having seen a doctor within the past month.
Among NSAID users, 53% were black compared to 64%
of non-NSAID users, and NSAID users were more likely
than non-NSAID users to have an education level greater
than high-school (38% versus 27%). There were no mater-
ial differences in any of the examined characteristics be-
tween those who reported non-use of NSAIDs and those
with unknown NSAID use.
The prevalence of hypertension (~80%) and hyperchol-
esterolemia (~50%) were similarly high among NSAID
users and non-users. Approximately one-third of NSAID
users reported a history of diabetes, one in five reported a
prior history of MI and 36% and 44% had a previous CMS
claim for CKD and heart failure, respectively. A higher
proportion of NSAID users reported a diagnosis of arth-
ritis compared to nonusers (71% versus 43%) and NSAID
users were more likely to also report regular use of low-
dose aspirin (44% vs. 37%), regular-dose aspirin (24% vs.
15%) and acetaminophen (35% vs. 14%).
Table 3 presents multivariable logistic regression-
derived odds ratios (OR) and 95% confidence intervals
(CI) for the association between various participant
characteristics and NSAID use among AKI survivors.
Neither sex [OR (male): 0.84; 95% CI: 0.54, 1.30], race
[OR (black): 0.81; 95% CI: 0.53, 1.24] nor education [OR
(≥high school): 1.51; 95% CI: 0.96, 2.40] was statistically
significantly associated with odds of NSAID use. Patients
with a history of arthritis had significantly increased
odds of using NSAIDs (OR: 3.00; 95% CI: 1.92, 4.68), as
did users of acetaminophen (OR: 2.43; 95% CI: 1.50,
3.93), while diabetes (OR: 0.44; 95% CI: 0.29, 0.69) and
CKD (OR: 0.63; 95% CI: 0.41-0.98) were inversely associ-
ated with NSAID use. Time since index AKI episode
was marginally statistically significant, while hyperten-
sion, heart failure and participant age were not signifi-
cant predictors of NSAID use.
Sensitivity analyses excluding from the models those
with unknown NSAID use or implementing alternate
multiple imputation methods yielded similar estimates
of association (see Additional file 2: Figure S2).
Discussion
Survivors of AKI are at increased risk for future kidney
dysfunction [19–21], cardiovascular complications [3, 21],
and death [22, 23]. In this study, we demonstrate that
nearly one in five AKI survivors were using NSAIDs regu-
larly and that the prevalence remained consistently high
regardless of time since the most recent AKI episode.
Alarmingly, over one-half of NSAID users were taking
these medications before and after the index AKI episode.
Further, we demonstrate that in this predominantly low-
income population, use of NSAIDs following AKI was
somewhat more likely among participants with arthritis
and those without diabetes.
The path to ESRD is often non-linear and marked by
one or more AKI episodes [24, 25]. The incidence of
AKI is also rising by approximately 10% per year [2],
highlighting a growing population of survivors in need
of follow-up care. While optimal care remains to be de-
fined, little debate exists regarding the adverse effects of
chronic NSAID use on the kidney and cardiovascular
systems. The use of NSAIDs in patients at risk or with
established CKD is a well-recognized problem, and was
recently emphasized by the ASN QPS Task Force as one
of five highest impact evidence-based areas in need of
improvement [26]. Patients who experience AKI, par-
ticularly when superimposed on CKD (36% of NSAID
users in our cohort), are at highest risk for ESRD and
thus represent a subgroup in whom preventing future
loss of kidney function may be especially important
[27, 28]. One potential mechanism for this increased
risk may be through recurrent AKI. We have recently
demonstrated that 25% of AKI survivors are re-
hospitalized with another AKI event within a year of
discharge [28]. This study adds to the literature by
pointing out a potentially modifiable risk factor for
preventing recurrent AKI.
Even in the absence of CKD, AKI has been demon-
strated to lead to impaired sodium handling and autore-
gulatory capacity [29, 30]. When coupled with NSAID
Table 3 Multivariable logistic regression-derived odds ratios
(OR) and 95% confidence intervals (CI) for the association
between participant characteristics and use of non-steroidal
anti-inflammatory drugs (NSAIDs) among 826 acute kidney injury
(AKI) survivors in the Southern Community Cohort Study (SCCS)
Associated factors ORa 95% CI
Enrollment Ageb 0.99 (0.97, 1.02)
Male sex 0.84 (0.54, 1.30)
Black race 0.81 (0.53, 1.24)
Income, >$15,000 vs. <$15,000 0.88 (0.52, 1.48)
Education, > high school vs. < high school 1.51 (0.96, 2.40)
Arthritis 3.00 (1.92, 4.68)
Hypertension 1.43 (0.82, 2.49)
Diabetes 0.44 (0.29, 0.69)
Years since AKIb 0.92 (0.80, 1.05)
Chronic kidney disease 0.63 (0.41, 0.98)
Heart failure 0.97 (0.63, 1.50)
Acetaminophen 2.43 (1.50, 3.93)
aAll variables were entered in the model simultaneously, along with a variable
indicating SCCS recruitment source (CHC vs. General Population)
bOR per 1 year increase
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use, which can increase sodium retention and blood
pressure [31, 32], these derangements may increase sus-
ceptibility to recurrent AKI [28], hypertension [1], and
cardiovascular events [3] in AKI survivors. The FDA has
also recently strengthened its warning regarding NSAIDs
and major vascular events, particularly among those
with traditional cardiovascular risk factors [9]. Diabetes,
MI, hypertension and heart failure were all common
among AKI survivors in our study. Participants with dia-
betes were less likely to use NSAIDs, perhaps due to
awareness of CKD risk among diabetic patients. Alterna-
tively, NSAIDs are not considered the optimal treatment
for neuropathic pain, which is common among diabetics.
Nevertheless, the combination of these comorbidities,
NSAID use and AKI may further enhance the vulner-
ability of this population to subsequent adverse kidney
and cardiovascular events. More proximal use of
NSAIDs may also impact recovery from AKI. This is of
particular concern since approximately 17% of patients
experiencing AKI within the past 3 or 6 months were
regularly taking NSAIDs.
A strong predictor of NSAID use in our study was a
history of arthritis. Although arthritis was self-reported
and likely included a mix of rheumatic disease, including
rheumatoid arthritis, osteoarthritis and ankylosing spon-
dylitis, osteoarthritis was the likely indication for NSAID
use for many of these patients. Osteoarthritis prevalence
in the US is rising [33], and while NSAIDs are effective
anti-inflammatory and analgesic agents, re-examination
of their risks and benefits has prompted decreased use
in this patient population [34]. Current clinical guide-
lines for osteoarthritis management recommend acet-
aminophen for pain relief as first-line therapy ahead of
oral NSAIDs [35], with rising pressure in some countries
to make all NSAIDs available by prescription only [36].
Increasing awareness of NSAID risks among AKI survi-
vors with arthritis, as well as other serious comorbidities,
may be especially important in light of concurrent ef-
forts to limit opioid use among these patients.
The prevalence of NSAID use among AKI survivors
was comparable to that in the SCCS cohort overall
(23%), and in a subset of the cohort restricted to those
with at least one CMS claim prior to SCCS enrollment
(23%; data not shown). Although recruited primarily
through CHCs and thus with similar healthcare access
regardless of race and income, the high rates of post-
AKI NSAID use in this low socioeconomic status popu-
lation are concerning in light of well-described dispar-
ities in the development and progression of CKD among
the poor [37, 38]. Without adjusting for other covariates,
black AKI survivors in our study were less likely to use
NSAIDs compared to whites; however, the difference is
not statistically significant when adjusting for socioeco-
nomic characteristics, education and comorbidities. This
also mirrors the pattern of NSAID use observed in the
SCCS population overall, in which 20% of blacks re-
ported NSAID use compared to 28% of whites. The
prevalence of CKD at baseline was somewhat higher
among blacks compared to whites (46% vs. 41%), and it
is possible that physicians may have greater recognition
of CKD risk among blacks and thus be less likely to pre-
scribe NSAIDs to them. However, OTC NSAID use was
also less common among blacks, and we cannot rule out
under-treatment of pain in this group.
There is a clear need to develop strategies to reduce
unnecessary NSAID use among AKI survivors, especially
as rates of regular NSAID use in this study were two to
three times greater than reported in studies of patients
with CKD [11, 39]. The higher prevalence of use may be
explained in part by our capture of both prescription
and OTC exposure, as well as by the geographic catch-
ment area of the SCCS, which overlaps with regions
shown to have higher utilization of prescriptions with
potentially harmful drug-disease interactions [40], in-
cluding in CKD. These findings support a critical role
for improving education and awareness of the potential
hazard of NSAID use. Research has already demon-
strated that patient awareness of CKD is low [41], and
awareness among AKI survivors of the potential nephro-
toxicity of NSAIDs may be similarly low [42]. As most
survivors of AKI will not be seen by a nephrology pro-
vider [43], the burden of risk reduction falls to patients
and their primary providers. The similar prevalence of
NSAID use among AKI survivors compared to the gen-
eral SCCS cohort suggests that increasing awareness
among both will be equally important as about 50% of
NSAID use in our study was by prescription.
Strengths of our study include capture of both prescrip-
tion and non-prescription NSAID use and its examination
within a lower socioeconomic patient population with a
high burden of risk factors for both CVD and kidney dis-
ease. While several million prescriptions for NSAIDs are
estimated to be written annually in the US [44], non-
prescription, OTC use is likely more common requiring
capture of information of both sources to understand the
full burden of use [45]. Moreover, comparison of black
and white participants of similar socioeconomic status
and comparable health care access minimizes confound-
ing effects related to socioeconomic status.
Limitations of the study include the use of administra-
tive data to identify prevalent AKI. However, multiple
studies have demonstrated that administrative codes are
specific and likely to capture more severe AKI [46],
highlighting the concerning prevalence of NSAID use
among the subset of AKI survivors at highest risk for ex-
periencing poor renal and cardiovascular outcomes [47].
Because our cohort is likely enriched for more severe
AKI, our findings also likely represent an underestimate
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of the overall burden of NSAID use among all survivors
of AKI. Similarly, the known sensitivity limitations of ad-
ministrative codes for detecting AKI precluded our abil-
ity to perform a meaningful analysis of the association of
NSAID use with future adverse events. However, the
prevalence of use in this population does set the stage
for further studies to determine the level of concern.
The study also relied on self-report of NSAID use, and
the wording of the questionnaire defined regular use as
use at least two times per week for one month or more,
which could result in some misclassification, particularly
with respect to specific type of analgesic used or dur-
ation of regular use. Although we accounted for several
participant characteristics or comorbidities (e.g. arthritis)
that may be associated with NSAID use, there remains a
possibility of residual confounding by indication from other
comorbidities, CKD stage or underlying causes or intensity
of pain that may be associated with NSAID use and for
which information was not available. Lastly, our study is
generalizable only to patients who survived an episode of
AKI without ESRD. Moreover, participants were drawn
from a population in the southeastern US with generally
low socioeconomic status, thus the findings of this study
may not be generalizable to other populations.
Conclusion
In summary, regular NSAID use is common (20%)
among socioeconomically disadvantaged AKI survivors.
The high prevalence of an avoidable risk factor in a
group at high risk for both kidney and cardiovascular
events is concerning and underscores the need to better
understand the association between NSAID use in this
population and future adverse events and in whom the
risks are highest, as well as the reasons for use and ef-
fective strategies to improve education and awareness
among physicians, patients and caregivers.
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with an observed outcome (PNG 82 kb)
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